Here’s Why Akero Therapeutics Is Surging Today
Here's Why Akero Therapeutics Is Surging Today 1Shares of Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biopharmaceutical company, are on the move after the company’s lead candidate succeeded in a controlled clinical trial. Investors impressed with the results have pushed the stock 22% higher as of 1:36 p.m. EDT on Tuesday. Non-alcoholic steatohepatitis (NASH) is a potentially fatal …
News story posted on 2020-03-31T22:14:00.0000000Z